D Bradley Welling,, Facs

List of Publications by Year
in descending order

136 papers	4,072 citations	101543 36 h-index	138484 58 g-index
139 all docs	139 docs citations	139 times ranked	3837 citing authors

#	Article	IF	Citations
1	Imbalance and dizziness caused by unilateral vestibular schwannomas correlate with vestibulo-ocular reflex precision and bias. Journal of Neurophysiology, 2022, 127, 596-606.	1.8	7
2	Aerosol Dispersion During Mastoidectomy and Custom Mitigation Strategies for Otologic Surgery in the COVIDâ€19 Era. Otolaryngology - Head and Neck Surgery, 2021, 164, 67-73.	1.9	32
3	New developments in neurofibromatosis type 2 and vestibular schwannoma. Neuro-Oncology Advances, 2021, 3, vdaa153.	0.7	17
4	Considerations in Management of Acute Otitis Media in the COVID-19 Era. Annals of Otology, Rhinology and Laryngology, 2021, 130, 520-527.	1.1	14
5	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611.	2.3	16
6	Systematic and Other Reviews: Criteria and Complexities. Annals of Otology, Rhinology and Laryngology, 2021, 130, 649-652.	1.1	3
7	Systematic and other reviews: Criteria and complexities. Head and Neck, 2021, 43, 1979-1982.	2.0	1
8	Systematic and Other Reviews: Criteria and Complexities. Journal of Voice, 2021, 35, 509-511.	1.5	0
9	Systematic and Other Reviews: Criteria and Complexities. Ear, Nose and Throat Journal, 2021, 100, 403-406.	0.8	0
10	Systematic and other reviews: Criteria and complexities. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2021, 7, 236-239.	1.6	3
11	Patient Report of Hearing in Neurofibromatosis Type 2. Neurology, 2021, 97, S64-S72.	1.1	4
12	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 2021, 16, e0252048.	2.5	19
13	Early phase clinical studies of <scp>AR</scp>â€42, a histone deacetylase inhibitor, for neurofibromatosis type 2â€associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology, 2021, 6, 1008-1019.	1.5	14
14	Pulmonary Embolism and Sigmoid Sinus Thrombosis After Translabyrinthine Vestibular Schwannoma Resection: A Retrospective Case Series. Annals of Otology, Rhinology and Laryngology, 2021, , 000348942110368.	1.1	0
15	Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Frontiers in Oncology, 2021, 11, 698192.	2.8	8
16	Idiopathic Sudden Sensorineural Hearing Loss: Speech Intelligibility Deficits Following Threshold Recovery. Ear and Hearing, 2021, 42, 782-792.	2.1	7
17	IMPROVING BARRIER DRAPES FOR THE MITIGATION OF AEROSOL AND PARTICULATE SPREAD DURING MASTOIDECTOMY. Otology and Neurotology, 2021, 42, 347-349.	1.3	2
18	Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction. Communications Medicine, 2021, 1, 44.	4.2	69

#	Article	IF	Citations
19	The natural progression of lowâ€frequency hearing loss in patients who meet hybrid implant system candidacy criteria. Laryngoscope, 2020, 130, 1299-1303.	2.0	1
20	Chronic Conductive Hearing Loss Is Associated With Speech Intelligibility Deficits in Patients With Normal Bone Conduction Thresholds. Ear and Hearing, 2020, 41, 500-507.	2.1	16
21	Expanded use of teleservices in otology and neurotology in response to the <scp>COVID</scp>â€19 (<scp>SARSâ€Cov</scp>â€2) pandemic. Laryngoscope Investigative Otolaryngology, 2020, 5, 950-953.	1.5	3
22	MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Frontiers in Cellular Neuroscience, 2020, 14, 191.	3.7	15
23	American Neurotology Society, American Otological Society, and American Academy of Otolaryngology â€“ Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic. Otology and Neurotology, 2020, 41, 1163-1174.	1.3	17
24	Topical fibroblast growth factorâ€2 for treatment of chronic tympanic membrane perforations. Laryngoscope Investigative Otolaryngology, 2020, 5, 657-664.	1.5	8
25	Airborne Aerosol Generation During Endonasal Procedures in the Era of COVIDâ€19: Risks and Recommendations. Otolaryngology - Head and Neck Surgery, 2020, 163, 465-470.	1.9	118
26	Endonasal instrumentation and aerosolization risk in the era of COVIDâ€19: simulation, literature review, and proposed mitigation strategies. International Forum of Allergy and Rhinology, 2020, 10, 798-805.	2.8	284
27	Providing health care to patients with hearing loss during <scp>COVID</scp>â€19 and physical distancing. Laryngoscope Investigative Otolaryngology, 2020, 5, 396-398.	1.5	14
28	Demonstration and Mitigation of Aerosol and Particle Dispersion During Mastoidectomy Relevant to the COVID-19 Era. Otology and Neurotology, 2020, 41, 1230-1239.	1.3	56
29	A Tribute to David J. Lim, MD: Researcher, Mentor, Organizer, and Friend. Annals of Otology, Rhinology and Laryngology, 2019, 128, 6S-7S.	1.1	0
30	Open access: is there a predator at the door?. Journal of Laryngology and Otology, 2018, 132, 189-190.	0.8	0
31	Open Access: Is There a Predator at the Door?. Annals of Otology, Rhinology and Laryngology, 2018, 127, 137-138.	1.1	1
32	Open Accessâ€"Is There a Predator at the Door?. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 289.	2.2	0
33	Open access: Is there a predator at the door?. Laryngoscope Investigative Otolaryngology, 2018, 3, 6-7.	1.5	1
34	Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Scientific Reports, 2018, 8, 5437.	3.3	14
35	Open Access: Is There a Predator at the Door?. Journal of Voice, 2018, 32, 1-2.	1.5	2
36	Open access: is there a predator at the door?. International Forum of Allergy and Rhinology, 2018, 8, 81-82.	2.8	2

#	Article	IF	Citations
37	Open access: Is there a predator at the door?. Laryngoscope, 2018, 128, 1255-1256.	2.0	0
38	Open Access: Is There a Predator at the Door?. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 115-116.	0.8	1
39	Reflections on the Last 25 Years of the American Otological Society and Thoughts on its Future. Otology and Neurotology, 2018, 39, S81-S94.	1.3	1
40	Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology, 2018, 299, 299-307.	4.1	31
41	Open Access: Is There a Predator at the Door?. OTO Open, 2018, 2, 2473974X17752132.	1.4	0
42	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350.	2.5	17
43	Open Access: Is There a Predator at the Door?. Otolaryngology - Head and Neck Surgery, 2018, 158, 401-402.	1.9	4
44	Otogenic brain abscesses: A systematic review. Laryngoscope Investigative Otolaryngology, 2018, 3, 198-208.	1.5	32
45	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget, 2017, 8, 31666-31681.	1.8	27
46	Cortical Auditory Evoked Potentials to Evaluate Cochlear Implant Candidacy in an Ear With Long-standing Hearing Loss. Annals of Otology, Rhinology and Laryngology, 2016, 125, 858-861.	1.1	2
47	Intracranial Schwannomas. , 2016, , 543-554.		0
48	Editorial. Laryngoscope Investigative Otolaryngology, 2016, 1, 5-5.	1.5	0
49	Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo. Scientific Reports, 2016, 6, 36215.	3.3	22
50	Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology, 2016, 18, 1265-1277.	1.2	24
51	A new open access journal. Laryngoscope, 2015, 125, 2001-2001.	2.0	0
52	Classics from the Laryngoscope. Laryngoscope, 2015, 125, 1031-1032.	2.0	1
53	Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget, 2015, 6, 1981-1994.	1.8	38
54	Do Adults With Cochlear Implants Rely on Different Acoustic Cues for Phoneme Perception Than Adults With Normal Hearing?. Journal of Speech, Language, and Hearing Research, 2014, 57, 566-582.	1.6	42

#	Article	IF	Citations
55	Neurophysiology of spectrotemporal cue organization of spoken language in auditory memory. Brain and Language, 2014, 130, 42-49.	1.6	3
56	LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene, 2014, 33, 3571-3582.	5.9	37
57	Comparison of Longâ€term Qualityâ€ofâ€Life Outcomes in Vestibular Schwannoma Patients. Otolaryngology - Head and Neck Surgery, 2014, 150, 1024-1032.	1.9	61
58	Wound breakdown after middle cranial fossa craniotomy: An unusual complication after rhytidectomy. Laryngoscope, 2014, 124, 554-557.	2.0	1
59	Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth. Cancer Research, 2013, 73, 792-803.	0.9	44
60	Detecting Soft Failures in Pediatric Cochlear Implants. Otology and Neurotology, 2013, 34, 1648-1655.	1.3	7
61	Minimal reporting standard for reporting hearing outcomes. Laryngoscope, 2013, 123, 303-303.	2.0	2
62	Threeâ€Dimensional Segmented Volumetric Analysis of Sporadic Vestibular Schwannomas. Otolaryngology - Head and Neck Surgery, 2012, 147, 737-743.	1.9	45
63	Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors. Otology and Neurotology, 2012, 33, 244-257.	1.3	15
64	Virtual temporal bone dissection system: OSU virtual temporal bone system. Laryngoscope, 2012, 122, S1-12.	2.0	88
65	Modification and comparison of minimally invasive cochleostomy techniques: A pilot study. Laryngoscope, 2012, 122, 1142-1147.	2.0	11
66	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope, 2012, 122, 174-189.	2.0	37
67	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	1.2	101
68	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology, 2011, 13, 983-999.	1.2	60
69	Melatonin: Can it Stop the Ringing?. Annals of Otology, Rhinology and Laryngology, 2011, 120, 433-440.	1.1	33
70	Creating a crossâ€institutional grading scale for temporal bone dissection. Laryngoscope, 2010, 120, 1422-1427.	2.0	33
71	Surgery of the Endolymphatic Sac. , 2010, , 411-428.		0
72	Training Otologic Surgical Skills Through Simulationâ€”Moving Toward Validation: A Pilot Study and Lessons Learned. Journal of Graduate Medical Education, 2009, 1, 61-66.	1.3	21

#	Article	IF	Citations
73	Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2. Clinical Cancer Research, 2009, 15, 5032-5039.	7.0	74
74	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. Journal of Neuro-Oncology, 2009, 93, 61-77.	2.9	48
75	Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer, 2009, 45, 1709-1720.	2.8	55
76	Molecular Biology of Vestibular Schwannomas. Methods in Molecular Biology, 2009, 493, 163-177.	0.9	7
77	Gene expression analysis of human otosclerotic stapedial footplates. Hearing Research, 2008, 240, 80-86.	2.0	28
78	Spinal Myxopapillary Ependymoma Metastatic to Bilateral Internal Auditory Canals. Annals of Otology, Rhinology and Laryngology, 2008, 117, 98-102.	1.1	13
79	Long-Term Follow-Up of Hearing Loss in Biotinidase Deficiency. Journal of Child Neurology, 2007, 22, 1055-1055.	1.4	5
80	Chondromyxoid Fibroma of the Temporal Bone: Case Report and Review of the Literature. Annals of Otology, Rhinology and Laryngology, 2007, 116, 922-927.	1.1	34
81	Does Packing the Eustachian Tube Impact Cerebrospin al Fluid Rhinorrhea Rates in Translabyrinthine Vestibular Schwannoma Resections?. Otology and Neurotology, 2007, 28, 934-938.	1.3	21
82	Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology and Head and Neck Surgery, 2007, 15, 341-346.	1.8	29
83	Cochlear Implantation in the Neurofibromatosis Type 2 Patient: Longâ€Term Followâ€up. Laryngoscope, 2007, 117, 1069-1072.	2.0	117
84	Nerve of Origin, Tumor Size, Hearing Preservation, and Facial Nerve Outcomes in 359 Vestibular Schwannoma Resections at a Tertiary Care Academic Center. Laryngoscope, 2007, 117, 2087-2092.	2.0	127
85	Bilateral cerebellopontine angle metastatic melanoma: a case report. Ear, Nose and Throat Journal, 2007, 86, 388-90.	0.8	4
86	Recurrence of isolated multiple myeloma in the skull base: a case report and review of the literature. Ear, Nose and Throat Journal, 2007, 86, 555-60.	0.8	3
87	Leaving a Lasting Impression: Ear Mold Impressions as Middle Ear Foreign Bodies. Annals of Otology, Rhinology and Laryngology, 2006, 115, 912-916.	1.1	23
88	The Molecular Biology of Vestibular Schwannomas: Dissecting the Pathogenic Process at the Molecular Level. Otology and Neurotology, 2006, 27, 197-208.	1.3	61
89	Cyclin D1 and D3 Expression in Vestibular Schwannomas. Laryngoscope, 2006, 116, 423-426.	2.0	14
90	Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice. Laryngoscope, 2006, 116, 2018-2026.	2.0	17

#	Article	IF	Citations
91	Regulation of the Neurofibromatosis 2 gene promoter expression during embryonic development. Developmental Dynamics, 2006, 235, 2771-2785.	1.8	27
92	Facial Nerve Monitoring Parameters As a Predictor of Postoperative Facial Nerve Outcomes after Vestibular Schwannoma Resection. Otology and Neurotology, 2005, 26, 728-732.	1.3	81
93	Angiofibrolipoma of the Ear Canal. Laryngoscope, 2005, 115, 1461-1462.	2.0	9
94	Current Concepts in the Evaluation and Treatment of Neurofibromatosis Type II. Otolaryngologic Clinics of North America, 2005, 38, 671-684.	1.1	28
95	Predictive Factors in Pediatric Stapedectomy. Laryngoscope, 2003, 113, 1515-1519.	2.0	37
96	cDNA Microarray Analysis of Vestibular Schwannomas. Otology and Neurotology, 2002, 23, 736-748.	1.3	91
97	Multiple Transcription Initiation Sites, Alternative Splicing, and Differential Polyadenylation Contribute to the Complexity of Human Neurofibromatosis 2 Transcripts. Genomics, 2002, 79, 63-76.	2.9	36
98	Virtual Temporal Bone Dissection: An Interactive Surgical Simulator. Otolaryngology - Head and Neck Surgery, 2002, 127, 79-83.	1.9	95
99	Retinoblastoma???Cyclin-Dependent Kinase Pathway Deregulation in Vestibular Schwannomas. Laryngoscope, 2002, 112, 1555-1561.	2.0	34
100	Longâ€Term Stapedectomy Results With the McGee Stapes Prosthesis. Laryngoscope, 2001, 111, 2060-2063.	2.0	16
101	Endolymphatic mastoid shunt surgery. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2001, 12, 133-136.	0.4	1
102	Expression of Cytokine and Chemokine Genes by Human Middle Ear Epithelial Cells Induced by Formalin-KilledHaemophilus influenzae or Its Lipooligosaccharide htrB and rfaD Mutants. Infection and Immunity, 2001, 69, 3678-3684.	2.2	42
103	The enlarged vestibular aqueduct syndrome. Current Opinion in Otolaryngology and Head and Neck Surgery, 2000, 8, 380-383.	1.8	3
104	Tumor Growth and Audiometric Change in Vestibular Schwannomas Managed Conservatively. Laryngoscope, 2000, 110, 1843-1849.	2.0	85
105	Endolymphatic mastoid shunt: A reevaluation of efficacy. Otolaryngology - Head and Neck Surgery, 2000, 122, 340-345.	1.9	60
106	Endolymphatic Mastoid Shunt: A Reevaluation of Efficacy. Otolaryngology - Head and Neck Surgery, 2000, 122, 340-345.	1.9	50
107	Analysis of the Human Neurofibromatosis Type 2 Gene Promoter and its Expression. Otolaryngology - Head and Neck Surgery, 2000, 123, 413-418.	1.9	11
108	Preoperative Antibiotics and Steroids in Vestibular Schwannoma Excision. Laryngoscope, 1999, 109, 1081-1083.	2.0	11

#	Article	IF	Citations
109	Transcochlear Repair of Persistent Cerebrospinal Fluid Leaks. Laryngoscope, 1999, 109, 1392-1396.	2.0	13
110	Hearing preservation in vestibular schwannoma surgery. Current Opinion in Otolaryngology and Head and Neck Surgery, 1999, 7, 244-247.	1.8	1
111	Clinical Manifestations of Mutations in the Neurofibromatosis Type 2 Gene in Vestibular Schwannomas (Acoustic Neuromas). Laryngoscope, 1998, 108, 178-189.	2.0	47
112	Middle fossa transpetrosal approach for petroclival and brainstem tumors. Laryngoscope, 1998, 108, 1408-1412.	2.0	21
113	Intracranial Tumors Mimicking Benign Paroxysmal Positional Vertigo. Otolaryngology - Head and Neck Surgery, 1998, 118, 429-436.	1.9	51
114	Melanoma of the Petrous Apex of the Temporal Bone. Annals of Otology, Rhinology and Laryngology, 1997, 106, 519-521.	1.1	6
115	Hemangioma of the Temporal Bone in a Patient Presumed to Have MÃ©niÃ¨reÊ¼s Syndrome. Southern Medical Journal, 1997, 90, 736-739.	0.7	14
116	The Treatment Of Hearing Loss In Menereâ€™s Disease. Otolaryngologic Clinics of North America, 1997, 30, 1123-1144.	1.1	20
117	Particulate Matter in the Posterior Semicircular Canal. Laryngoscope, 1997, 107, 90-94.	2.0	156
118	Inner and Middle Ear Hyperbaric Oxygen-Induced Barotrauma. Laryngoscope, 1997, 107, 1350-1356.	2.0	32
119	Submillimeter Magnetic Resonance Imaging of the Temporal Bone in Meniere's Disease. Laryngoscope, 1996, 106, 1359-1364.	2.0	26
120	Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Human Genetics, 1996, 98, 189-193.	3.8	68
121	Safety of ototopical antibiotics. Laryngoscope, 1995, 105, 472-474.	2.0	39
122	Effects of vestibular rehabilitation and social reinforcement on recovery following ablative vestibular surgery. Laryngoscope, 1995, 105, 686-692.	2.0	54
123	Repair of chronic tympanic membrane perforations with long-term epidermal growth factor. Laryngoscope, 1995, 105, 1300-1304.	2.0	46
124	Cervical Lymphangioma with Simultaneous Skull Base Invasion and Soft Tissue Regression. Annals of Otology, Rhinology and Laryngology, 1995, 104, 662-664.	1.1	6
125	Particle repositioning maneuver for benign paroxysmal positional vertigo. Laryngoscope, 1994, 104, 946-949.	2.0	68
126	Insertional trauma of multichannel cochlear implants. Laryngoscope, 1993, 103, 995-1001.	2.0	65

#	Article	IF	Citations
127	Management of Carotid Artery Hemorrhage in Middle Ear Surgery. Otolaryngology - Head and Neck Surgery, 1993, 109, 996-999.	1.9	19
128	Effect of Head Orientation on the Diagnostic Sensitivity of Posturography in Patients with Compensated Unilateral Lesions. Otolaryngology - Head and Neck Surgery, 1992, 106, 355-362.	1.9	35
129	Avulsion of the Anomalous Facial Nerve at Stapedectomy. Laryngoscope, 1992, 102, 729-733.	2.0	23
130	Implantable Bone Conduction Hearing Device. Laryngoscope, 1992, 102, 1200.	2.0	0
131	Unilateral Sensorineural Hearing Loss Rehabilitation. Otolaryngology - Head and Neck Surgery, 1991, 105, 771-778.	1.9	9
132	Acoustic Neuroma: A Costâ€Effective Approach. Otolaryngology - Head and Neck Surgery, 1990, 103, 364-370.	1.9	116
133	Facial Nerve Function Following Irradiated Cable Grafts. Laryngoscope, 1989, 99, 27???34.	2.0	25
134	Management of Bilateral Acoustic Tumors. Laryngoscope, 1989, 99, 475???484.	2.0	22
135	Glomus Tympanicum Tumors. Laryngoscope, 1989, 99, 875???884.	2.0	46
136	Petrous Apex Cholesteatoma. Otolaryngologic Clinics of North America, 1989, 22, 981-1002.	1.1	28